ImmunoPrecise Antibodies Ltd (IPA) concluded trading on Thursday at a closing price of $2.31, with 5.24 million shares of worth about $12.1 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 258.42% during that period and on July 24, 2025 the price saw a gain of about 26.92%. Currently the company’s common shares owned by public are about 45.77M shares, out of which, 39.68M shares are available for trading.
Stock saw a price change of 32.76% in past 5 days and over the past one month there was a price change of 145.74%. Year-to-date (YTD), IPA shares are showing a performance of 171.76% which increased to 461.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.27 but also hit the highest price of $2.32 during that period. The average intraday trading volume for ImmunoPrecise Antibodies Ltd shares is 2.25 million. The stock is currently trading 44.49% above its 20-day simple moving average (SMA20), while that difference is up 123.06% for SMA50 and it goes to 287.25% higher than SMA200.
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) currently have 45.77M outstanding shares and institutions hold larger chunk of about 8.70% of that.
The stock has a current market capitalization of $105.71M and its 3Y-monthly beta is at 0.57. It has posted earnings per share of -$1.13 in the same period. It has Quick Ratio of 2.11 while making debt-to-equity ratio of 0.51. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IPA, volatility over the week remained 13.12% while standing at 16.28% over the month.
Stock’s fiscal year EPS is expected to rise by 41.22% while it is estimated to increase by 82.54% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 02, 2022 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by The Benchmark Company stated ImmunoPrecise Antibodies Ltd (IPA) stock as a Buy in their note to investors on October 25, 2021, suggesting a price target of $12 for the stock.
